Viatris Pharmaceuticals’ applications for generic options for type 2 diabetes drug Ozempic and weight loss drug Wegovy are now under regulatory review, according to
the company’s second quarter presentation
.
If approved, both would be the first generics to market for the blockbuster drugs.
But Novo Nordisk has already taken steps to stop Viatris from bringing a Wegovy generic to market with a lawsuit filed in January in Delaware District Court. In court filings, lawyers for Novo wrote that the lawsuit comes from Viatris’ submission of an abbreviated NDA to the FDA for a Wegovy generic injection prior to the patents’ expiration.